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Immunomodulatory effects of interferon-g on autoreactive cells to (C57BL/6 3 DBA/2) F1 (B6D2 F1) hybrid recipi-
nephritogenic T-cell clones. ents [1]. This multisystem autoimmune disorder com-
Background. We examined the immunomodulatory effects prises a spectrum of abnormalities such as vasculitis,of interferon-g (IFN-g) on renal-derived CD41 a/b1 T cells,
polyarthritis, and mononuclear cell infiltration of multi-called mouse renal (MR) cells, isolated from animals with mu-
rine chronic graft-versus-host disease, a model of autoimmune ple organs [2, 3]. A variety of circulating and deposited
glomerulonephritis. MR T cells express a Th2 cytokine profile, autoantibodies are also detected in affected animals, in-
although IFN-g expression is also detected in a subset of clones cluding anti-DNA, antihistone, and antilaminin antibod-that adoptively transfers renal disease to naive recipients. In
ies, that are produced by autoreactive host B cells [4–7].view of disparate patterns of IFN-g expression, we evaluated
B6D2 F1 recipient animals with cGVHD develop anthe effects of exogenous IFN-g on nephritogenic (MR1.3) and
nonnephritogenic (MR1.6) clonal activity. immune-complex glomerulonephritis within two to four
Methods. These studies examined IFN-g–mediated effects weeks following the transfer of parental T cells, associ-
on clonal proliferation, cytokine production, nephritogenic po-
ated with progressive mononuclear (T cell) parenchymaltential, and IFN-g receptor expression.
infiltration, ultimately resulting in an end-stage renalResults. IFN-g mediated dose-dependent inhibition of MR1.3
and MR1.6 proliferation. This cytostatic effect was not medi- lesion in all recipients [3, 6].
ated by inhibiting cytokine genes, as expression of interleukin In this murine model of cGVHD, immunocompetent
(IL)-4, IL-10, IL-13, and IFN-g after IFN-g treatment was
DBA/2 parental T cells are activated on transfer bynot markedly altered in either clone, although baseline IL-13
B6D2 F1 host alloantigens, a process initiating a systemicexpression was enhanced in MR1.6. IFN-g markedly altered
the functional phenotype of MR1.6, as pretreated recipients autoimmune disease [8, 9]. Mechanisms by which host
developed severe mononuclear cell infiltrates and tubular dam- tissues are damaged, however, remain unclear. Studies
age following adoptive transfer of MR1.6. Neutralizing anti–
from other investigators suggest that T-cell–derived pro-IFN-g antibodies did not inhibit MR1.3 nephritogenicity, but
inflammatory cytokines, such as interferon-g (IFN-g),did block MR1.6-induced disease in IFN-g–treated mice. Al-
though both clones constitutively expressed the IFN-g receptor can mediate parenchymal damage and may play an im-
b chain, IFN-g exposure decreased its expression in MR1.3 cells, portant role in the development of renal disease in
but did not markedly change its expression in MR1.6 cells. cGVHD [10]. Alterations in the cytokine network mayConclusion. These studies describe an unusual permissive
provide a final common pathway of target organ damagerole for IFN-g in modulating nephritogenic Th2 activity in vivo,
which facilitates the initiation of cell-mediated autoimmune in the setting of activation and expansion of autoreactive
renal injury. Apparent differential effects of IFN-g on distinct T-cell subsets [10].
T-cell clones may be mediated in part by alterations in cytokine
Previous studies in our laboratory have characterizedreceptor expression.
autoreactive B6D2 F1 CD41 a/b1 T cells derived from
diseased kidneys of animals with cGVHD [11]. Two func-
tional subsets of mouse renal (MR) T-cell clones wereMurine chronic graft-versus-host disease (cGVHD) is
isolated. One subset is nephritogenic, restricted by Iad,induced following the transfer of parental (DBA/2) T
and adoptively transfers tubulointerstitial inflammation
and damage to syngeneic recipients [11]. The other sub-Key words: nephritis, T cell lymphocyte, graft vs. host disease, cyto-
kines, autoimmunity, MHC. set does not transfer renal disease to syngeneic animals
and is Iab reactive [11]. Both nephritogenic and non-
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however, that MR T-cell clones that transfer renal dis- role for IFN-g in the cell-mediated renal lesion observed
in this model of autoimmune glomerulonephritis, butease also secrete low levels of IFN-g [11]. These T-cell
clones are designated Th2 in view of their marked pro- also indicate that pathogenic T-cell lymphocytes can
elicit parenchymal injury by other cytokine-mediatedduction of IL-4 and IL-10 on stimulation, with minimal
IFN-g production [11]. We were particularly interested pathways.
in the differential IFN-g expression in MR clones in view
of the proscriptive influence of IL-10 on its synthesis in
METHODS
CD41 T-cell clones and its more characteristic expres-
Micesion in Th1 cells [12].
Interferon-g is a multifunctional lymphokine with in- B6D2 F1 (H-2b/d) were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA).ducible expression predominantly in T-cell lymphocytes
as well as natural killer (NK) cells [10]. It is a proinflam-
T-cell clonesmatory cytokine that has a variety of stimulatory activi-
ties. IFN-g increases high-affinity Fcg receptor I expres- Mouse renal T-cell clones, MR1.3 and MR1.6, were
propagated by weekly passage with 10% MLA-144 su-sion on mononuclear phagocytes, augments expression
of intercellular adhesion molecule-1 expression on vari- pernatants as a source of IL-2 and other growth factors,
renal antigen preparation derived from normal B6D2 F1ous cell types, and increases B-7 costimulatory molecule
expression on antigen-presenting cells (APCs) (mono- kidneys (10 mg/ml) and 5 3 106 irradiated (2500 rads)
syngeneic B6D2 F1 spleen cells. T-cell culture mediumcytes) [13–15]. IFN-g is critical to differentiation and
maturation of mononuclear phagocytes and activation of consisted of RPMI 1640 (Life Technologies, Inc., Gaith-
ersburg, MD, USA) supplemented with glutamine,tissue macrophages [10]. Most notably, IFN-g increases
class II major histocompatibility complex (MHC) gene antibiotics (penicillin, streptomycin, gentamicin), 10%
decomplemented fetal calf serum (FCS), 5% NCTCtranscription and cell-surface expression on APC and
induces de novo class II MHC expression on various (Whittaker Bioproducts, Inc., Walkersville, MD, USA),
and 2 3 1025m 2-mercaptoethanol. Typically, wells be-other cells, such as renal epithelial cells, perhaps con-
verting them to “nonprofessional” APC [16–18]. Investi- came confluent at five to seven days and were carried
every 10 to 14 days. All T cells were cultured at 378C ingators also suggest that T-cell–derived IFN-g is an impor-
tant mediator of inflammatory reactions mediated by a 5% CO2 incubator.
CD41 T-cell clones [19]. Moreover, IFN-g–induced up-
Proliferation assaysregulation of class II MHC expression on renal epithelial
cells in vivo may be a crucial event in local trafficking Mouse renal T-cell clones (1 3 105) harvested from
day 7 to 9 cultures were added to anti-CD3 antibody-of autoimmune CD41 T cells in diseased kidneys [16–18].
In view of the disparate patterns of IFN-g expression coated plates (1 mg/ml) or were irradiated (2500 rads)
B6D2 F1 splenocytes (5 3 104) with renal antigen prepa-in functional MR clonal subsets, we further evaluated the
effects of exogenous IFN-g on nephritogenic (MR1.3) and ration (10 mg/ml), with 200 ml T-cell medium with various
doses of recombinant mouse IFN-g (PharMingen, Inc.,non-nephritogenic (MR1.6) T-cell clones. In vitro studies
indicate that IFN-g mediates dose-dependent inhibition San Diego, CA, USA) [11]. For all studies, cells were
pulsed with 3HTdR at 48 hours and were then harvestedof MR1.3 and MR1.6 proliferation, although cytokine
gene expression of IL-4, IL-10, IL-13, and IFN-g after at 72 hours for scintillation counting. Values represent
the mean of triplicate samples 6 sd.IFN-g exposure is not markedly altered in either T-cell
clone. In vivo analyses, with adoptive transfers to IFN-
Adoptive transfer of diseaseg–pretreated mice, demonstrate that the otherwise non-
nephritogenic clone, MR1.6, induces cortical inflamma- Renal subcapsular transfers were performed with na-
ive 6- to 12-week-old B6D2 F1 mice. T cells were har-tion with focal mononuclear cell infiltrates and tubular
dilatation and atrophy. Consistent with proinflammatory vested at end passage (day 10 to 14) and were washed
with phosphate-buffered saline (PBS), and aliquots ofeffects of IFN-g, renal class II MHC (I-Ab) expression
was enhanced in kidneys of all IFN-g pretreated mice. 10 3 106 in approximately 75 ml of PBS were injected
under the kidney capsule with a 30-gauge needle. ThisSimilar adoptive transfers with neutralizing anti–IFN-g
antibodies, however, did not alter the nephritogenic po- volume uniformly lifted the capsule off from most of
the parenchyma without bleeding. Some recipients weretential of MR1.3, but did inhibit MR1.6 nephritogenicity
in IFN-g–treated mice. Further analysis of IFN-g recep- pretreated with i.p. IFN-g (1000 U; PharMingen) or PBS
24 hours prior to adoptive transfer. For some MR1.3tor b (IFN-gRb)-chain expression reveals constitutive
expression in both MR1.3 and MR1.6, with distinct dif- and MR1.6 adoptive transfers, anti-IFN-g (R4-6 A2;
PharMingen) or rat IgG (Pierce, Rockford, IL, USA)ferences in expression levels on IFN-g exposure in these
MR clones. These studies suggest an immunomodulatory antibody was coadministered to recipient mice. The
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doses of anti–IFN-g antibody selected, 2.0 mg and 6.0 antibody (PBS) and staining with an irrelevant primary
antibody (normal mouse IgG).mg, were sufficient to neutralize the antiviral activity of
670 U and 2000 U IFN-g activity, respectively (Phar-
Northern blot hybridizationMingen). Three to seven days later, the kidneys were
harvested and longitudinally sectioned with preservation Total RNA isolated from 10 3 106 T cells was fraction-
ated on a 1.5% agarose-formaldehyde gel and thenof the subcapsular cell layer. Sections of kidney tissue
for immunohistochemistry were embedded in OCTTM transferred to a Zetabind membrane (Cuno Laboratory
Products, Meriden, CT, USA). Blots were hybridized tocompound (Miles Inc., Elkhart, IN, USA), snap frozen
in liquid nitrogen, and stored at 2708C. Other kidney 32P-labeled (Amersham Corp., Arlington Heights, IL,
USA) murine probes (specific activity of 2.0 3 109 dpm/sections were fixed in 10% buffered formalin, were paraf-
fin embedded for staining (hematoxylin and eosin and mg) for 16 hours at 558C. Probes for IL-10 [21], IFN-g
[22], IL-13 [23], IFN-gRb chain [24], and b-actin [25]periodic acid-Schiff), and examined for histological evi-
dence of disease. were used in these studies. After hybridization, the blots
were washed three times with 0.1 3 standard saline ci-
Assessment of renal disease trate/0.1% sodium dodecyl sulfate at 658C for 30 minutes.
Autoradiography was performed with intensifyingSemiquantitative methods assessed renal disease in
affected kidneys. Sections of paraffin-embedded tissue screens at 2708C. Some exposed films were scanned with
a laser densitometer (Hoefer, San Francisco, CA, USA),(4 mm) were stained with hematoxylin and eosin and
periodic acid-Schiff, and were examined for cellular in- and relevant mRNA levels were calculated relative to
those of b-actin.filtrates and tubular atrophy by an individual blinded
to the experimental protocol (C.M.M.). Stained kidney
Secreted cytokine measurementssections were evaluated with two different grading scales.
The severity of interstitial involvement was qualitatively The production of IL-4, IL-10, IL-13, and IFN-g by
T-cell clones was measured in cell-free culture superna-assessed with a scale used in previous studies [20]: 0 5
no involvement from the subcapsular cell layer; 0.5 5 tants by cytokine-specific enzyme-linked immunosor-
bent assay (ELISA). Supernatants were obtained fromtrace pathologic changes of cellular involvement in a
focal pattern in the outermost cortical tubular area; 1 5 end-passage T-cell clones (1 to 2 3 106/ml) plated for 24
hours with fresh T-cell media in the presence or absencesuperficial, focal peritubular infiltration and tubular atro-
phy under the transferred cell layer; 2 5 focal, deeply of immobilized anti-CD3 antibody (1 mg/ml) and various
doses of IFN-g. To determine IL-4, IL-10, and IFN-gextending, heavy cellular infiltrates with peritubular
damage and tubular atrophy. The sections were also levels, purified anticytokine capture monoclonal anti-
body (PharMingen, Inc.) was diluted to 1.0 mg/ml in 0.1graded by approximating the tubular layer cell depth of
the most advanced infiltrating front of mononuclear cells. m NaHCO3, pH 8.2, and 50 ml aliquots added to wells
of an ELISA plate. Following overnight incubation atEach layer equaled a tubular diameter and was given
one point. The data from both methods were expressed 48C and washing with PBS/0.05% Tween, wells were
blocked with 200 ml PBS/10% FCS at room temperatureas a mean for each group 6 sem.
for two hours, washed again with PBS/0.05% Tween,
Immunohistochemistry and then coated with cytokine standards and T-cell clone
supernatants diluted in PBS/10% FCS in duplicate.Frozen kidney sections were stained for class II MHC
(I-Ab; PharMingen, Inc.) using the avidin-biotin-peroxi- Plates were incubated overnight at 48C, washed with
PBS/0.05% Tween, and coated with 100 ml aliquotsdase complex, ABC technique (Vector Laboratories,
Burlingame, CA, USA). Frozen sections were fixed in of biotinylated anticytokine-detecting antibody (Phar-
Mingen) diluted to 1 mg/ml in PBS/10% FCS. Followingchilled (2208C) acetone, air dried, rehydrated in PBS,
and incubated with the avidin-biotin blocking reagent a 45-minute incubation at room temperature, the plates
were washed with PBS/0.05% Tween, coated with 100(Vector Laboratories) for 60 minutes. Appropriate dilu-
tions of the primary antibody were applied, and the slides ml aliquots of avidin-peroxidase (Sigma, St. Louis, MO,
USA) diluted in PBS/10% FCS, and incubated again atwere incubated for 60 minutes. Slides were washed in
PBS and then incubated with biotinylated antimouse IgG room temperature for 30 minutes. The plates were then
washed with PBS/0.05% Tween, and 100 ml aliquots of(Vector Laboratories) for 60 minutes. Following another
PBS wash, slides were incubated with the Vectastain peroxidase substrate reagent (Bio-Rad, Hercules, CA,
USA) were added to each well, allowed to develop atABC reagent (Vector Laboratories) for an additional 60
minutes. Slides were then incubated with diaminobenzi- room temperature for 5 to 10 minutes, and read on an
ELISA plate reader at 405 nm. Sensitivity limits for thedine (Vector Laboratories) and counterstained with he-
matoxylin (Fisher Scientific, Medford, MA, USA). Con- ELISA were IL-4, 30 pg/ml; IL-10, 30 pg/ml; and IFN-g,
0.3 U/ml. IL-13 levels were determined using the Quan-trol sections consisted of staining without primary
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tikine M IL-13 assay kit (R&D Systems, Minneapolis, antiproliferative doses of IFN-g (from 0.1 U/ml to 1000
U/ml). As shown in Figure 2, message expression of IL-MN, USA) in accordance with manufacturer’s instruc-
tions. Sensitivity limits for the assay were 1.5 pg/ml. 10, IL-13, and IFN-g was not markedly altered in either
MR1.3 or MR1.6 after IFN-g treatment at doses that
Statistical analysis significantly inhibited proliferation. Of note, Northern
hybridization studies in Figure 2 also revealed a signifi-Differences between experimental groups were deter-
mined, where appropriate, by Student’s t-test [26]. Statis- cant difference in IL-13 expression between MR1.3 and
MR1.6. Following stimulation, IL-13 was expressed attical significance between groups of adoptively trans-
ferred renal lesions was determined by Kruskal–Wallis relatively low levels in MR1.3 cells, whereas the non-
nephritogenic clone MR1.6 expressed much higher mes-one-way analysis of variance by ranks and the Mann–
Whitney U-test [26]. sage levels. Additional Northern hybridization studies
evaluating IL-4 expression in IFN-g–treated MR1.3 and
MR1.6 did not reveal marked differences in IL-4 tran-
RESULTS
scription between these T-cell clones (data not shown).
Interferon-g–mediated effects on mouse renal T-cell Analysis of secreted cytokines in supernatants of IFN-
clonal proliferation g–treated MR1.3 and MR1.6 T-cell clones corroborated
initial Northern hybridization studies (Table 1). Quanti-Recent reports indicate that IFN-g inhibits in vitro
proliferation of CD41 Th2 clones, but not IFN-g– tative assessment of secreted cytokines was performed,
by ELISA, on a panel of anti-CD3 antibody-stimulatedproducing Th1 clones [27, 28]. To investigate whether
IFN-g–producing nephritogenic Th2-like MR T-cell T-cell clones that were treated with various doses of
IFN-g (0.1 to 1000 U/ml). As shown in Table 1, superna-clones were also inhibited by this proinflammatory cyto-
kine, we compared proliferative responses of MR1.3 with tants from nephritogenic clone MR1.3 contained signifi-
cant amounts of IL-4, IL-10, and IL-13 and, consistentMR1.6, a nonnephritogenic Th2 clone, in the presence
of exogenous IFN-g. For these studies, proliferation of with our Northern hybridization data, also contained low
levels of IFN-g. MR1.6, which does not induce renalMR1.3 and MR1.6 to immobilized anti-CD3 antibody
was evaluated after incubation with varying doses of inflammation, expressed IL-4, IL-10, and IL-13, but not
IFN-g after stimulation. MR1.6 cells, however, consis-IFN-g. This route of T-cell stimulation was selected for
these studies, as it eliminates potential non–T-cell recep- tently produced more IL-13 than MR1.3 cells with anti-
CD3 antibody stimulation. Also consistent with initialtor-mediated stimuli associated with spleen cells prepa-
rations [27]. In this setting, the response of distinct T-cell Northern analyses, no marked changes in IL-4, IL-10,
IL-13, and IFN-g secretion were apparent after IFN-gclones to triggering via the TCR complex can be uni-
formly examined. As anticipated, the proliferative re- treatment. These studies suggest that both MR1.3 and
MR1.6 stimulated via the TCR complex, in the presencesponse of nonnephritogenic Th2 clone MR1.6 was pro-
foundly diminished by IFN-g (Fig. 1A). Studies presented of IFN-g, are capable of producing relevant cytokines
(particularly IL-4), but that they do not proliferate inin Figure 1A also reveal a similar dose-dependent inhibi-
tion of proliferation with the Th2-like nephritogenic response to autocrine or paracrine cytokine growth fac-
tors generated in this setting.clone MR1.3. Despite producing IFN-g, MR1.3 exhibits
a typical cytostatic Th2 response to exogenously added
Nephritogenic potential of MR1.3 and MR1.6 inIFN-g. Further proliferation studies conducted with
interferon-g–treated recipientsMR1.3 and MR1.6 stimulated with irradiated B6D2 F1
splenocytes in the presence of various concentrations of To assess IFN-g–mediated effects on the nephrito-
genic potential of renal-derived MR T-cell clones, weIFN-g are shown in Figure 1B. These assays demonstrate
that IFN-g inhibits both anti-CD3 antibody-mediated performed adoptive transfer studies with B6D2 F1 mice
pretreated with IFN-g before renal subcapsular transfer.and APC-induced Th2 proliferation responses.
In previous studies, we have found that renal subcapsular
Cytokine gene expression in interferon-g–treated transfer of immunocompetent T cells is a sensitive and
mouse renal T-cell clones reproducible means of determining the ability of discrete
T-cell subsets to elicit inflammation in renal parenchymaIn view of the antiproliferative effects of IFN-g on
both nephritogenic and non-nephritogenic clones, we [20, 29, 30]. We therefore used this technique to compare
the nephritogenic potential of MR T cells under a varietyalso examined the impact of various levels of IFN-g
exposure on MR T-cell clone cytokine gene expression. of experimental conditions. As shown in Figure 3 A and
B, IFN-g pretreatment did not alter the usual patternThese studies addressed whether IFN-g blocked TCR-
stimulated proliferation by inhibiting lymphokine pro- of interstitial disease induced by nephritogenic clone
MR1.3, which is characterized by focal cortical areas ofduction. Immobilized anti-CD3 antibody-stimulated
MR1.3 or MR1.6 T cells were incubated with various mononuclear cell infiltration and areas of tubular dilata-
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Fig. 1. Proliferative responses of mouse renal (MR) clones. MR T-cell clones (1 3 105), either MR1.3 or MR1.6, were added to (A) anti-CD3
antibody-coated plates (1 mg/ml) or (B) irradiated B6D2F1 splenocytes with renal antigen (10 mg/ml), with various concentrations of interferon-g
(IFN-g). Cells were pulsed with 3HTdR at 48 hours and were then harvested at 72 hours for scintillation counting. The values represent the mean
of triplicate samples 6 sd.
tion and damage. In contrast, IFN-g pretreatment did and costimulatory molecule expression on relevant APC
alter the nephritogenicity of clone MR1.6. In this setting, [16]. In view of renal tubular epithelial cell respon-
MR1.6 induced cortical inflammation with focal mono- siveness to these effects, we examined class II MHC
nuclear cell infiltrates and tubular dilation and atrophy expression shortly after adoptive transfer of MR1.3 and
(Fig. 3 C, D) in kidneys of syngeneic mice. The histologic MR1.6 T cells to syngeneic mice. Kidney sections from
features in all of these MR1.6-induced lesions are similar animals that received MR1.3 cells exhibited an increase
to those induced by the T-cell clone MR1.3. Formal in renal tubular class II MHC (I-Ab) staining, whether
histologic grading of these four groups, as well as IFN-g animals were pretreated with PBS (Fig. 4A) or IFN-g
and PBS controls, is shown in Table 2. Analysis of adop-
(Fig. 4B). Adoptive transfer of MR1.6 with PBS did nottive transfers demonstrates that both the severity and
increase I-Ab expression (Fig. 4C), but a marked increasedepth of MR1.6-induced renal lesions in IFN-g–treated
in renal class II MHC expression was noted if animalsrecipients are comparable to tubulointerstitial lesions
were pretreated with IFN-g prior to MR1.6 transfer (Fig.elicited by MR1.3. Treatment with IFN-g or PBS alone
4D). These studies also indicate that pretreatment ofdid not induce renal inflammation or damage.
animals with IFN-g alone (Fig. 4E), but not PBS (Fig.As previously stated, proinflammatory effects of
4F), induced mild increases in renal class II MHC expres-IFN-g on various subsets of immune cells may, in part,
be mediated by its ability to up-regulate class II MHC sion.
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Fig. 2. Cytokine expression in mouse renal
(MR) clones following interferon-g (IFN-g)
pretreatment. Nephritogenic (MR1.3) and non-
nephritogenic (MR1.6) clones (3 3 106/ml) were
plated on immobilized anti-CD3 antibody (1 mg/
ml) and various concentrations of IFN-g. After
24 hours, clonal RNA was harvested from 1 3
107 viable cells and evaluated for cytokine ex-
pression with cytokine-specific probes, interleu-
kin (IL)-10, IL-13, and IFN-g.
Table 1. Secreted cytokines produced by MR1.3 and MR1.6 In further studies, MR1.6 cells were administered to
IFN-g–pretreated recipients with anti–IFN-g antibodyIL-4 IL-10 IL-13
Cultured IFN-g dose IFN-g or with control rat IgG. As delineated in Table 3,T cell clonea U/ml ng/ml U/ml
anti–IFN-g antibodies effectively inhibited the renal le-
MR1.3 0 8.0 1450 21 2.5 sion typically induced by MR1.6 in IFN-g–pretreatedMR1.3 1 7.0 800 22 2.5
mice. Following adoptive transfer of MR1.6, no evidenceMR1.3 10 10 1700 20 4.5
MR1.3 100 9.0 1300 19 14 of tubulointerstitial damage was apparent in kidneys
MR1.3 1000 14 1400 20 2.5 from animals that received the neutralizing anti–IFN-g
MR1.6 0 10 600 110 ND
antibody, whereas kidneys from the control IgG groupMR1.6 1 14 800 115 ND
MR1.6 10 12 250 115 ND of IFN-g–pretreated animals exhibited marked renal in-
MR1.6 100 12 750 110 ND flammation and injury (Table 3). Unlike the MR1.3
MR1.6 1000 11 350 110 ND transfers, these studies suggest that IFN-g directly facili-
a MR T cell clones were harvested from day 10 cultures and plated in fresh tates MR1.6 nephritogenicity.
medium at 1.5 3 106 cells/ml. Clones were then stimulated with anti-CD3 anti-
body-coated plates (1 mg/ml) and various doses of IFN-g for 24 hours. The levels
Interferon-gRb chain expression in mouse renalof IL-4, IL-10, IL-13, and IFN-g in the resulting supernatants were determined
by cytokine-specific ELISA. ND, not detected. T-cell clones
To investigate potential mechanisms of differential
IFN-g–mediated effects in MR1.3 and MR1.6 cells, we
examined the expression of the IFN-gRb chain in viewEffects of neutralizing anti–interferon-g antibody on
of its critical signaling role in IFN-g–sensitive T cellsadoptive transfer of renal disease
[24, 31]. As shown in Figure 5, unstimulated MR1.3 and
As our nephritogenic clones secrete IFN-g following MR1.6 constitutively expressed IFN-gRb chain mRNA,
in vitro activation, we also evaluated the effects of neu- but they responded differently to stimulation in the pres-
tralizing anti–IFN-g antibodies on adoptive transfer of ence of IFN-g. Densitometric analysis of b-chain mes-
renal disease. For these studies, MR1.3 cells were coad- sage levels revealed an approximate 50% decrease in
MR1.3 cells, whereas levels in MR1.6 cells in this settingministered with anti–IFN-g antibody or with control rat
did not change markedly. Although both T-cell clonesIgG. As shown in the histology scores of Table 2, the
express the regulatory b chain following IFN-g exposure,severity and extent of tubulointerstitial lesions induced
differential regulation of the level of cytokine receptorby MR1.3 were not markedly different in either of these
expression may indeed effect distinct functional influ-treated groups. Transfer of MR1.3 to animals that were
ences of IFN-g on these T-cell clones.also treated with anti–IFN-g antibody or control rat IgG
did not alter the nephritogenic potential of this T-cell
DISCUSSIONclone. Moreover, renal class II MHC expression was
still apparent in early lesions in all anti–IFN-g antibody- In the studies presented here, we evaluated the immu-
nomodulatory effects of exogenous IFN-g on distincttreated mice (data not shown).
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Fig. 3. Effects of interferon-g (IFN-g) on ad-
optive transfers. For these studies, 5 3 106
mouse renal (MR) T-cell clones were injected
beneath the renal capsule of B6D2 F1 mice 24
hours after pretreatment with either PBS or
IFN-g (1000 U). Kidneys were harvested five
to seven days after T-cell transfers and were
evaluated by light microscopy. The interstitial
lesion typically seen after transfer of MR1.3 cells
is seen in both (A) (PBS pretreatment) and (B)
(IFN-g pretreatment). Focal cortical areas of
mononuclear cell infiltration are evident, as well
as areas of tubular dilation. MR1.6 adoptive
transfers are shown in (C) (PBS pretreatment)
and (D) (IFN-g pretreatment). IFN-g or PBS
pretreatment alone did not result in renal in-
flammation or damage (data not shown).
functional CD41 T cells derived from diseased kidneys of MR1.6 T cells. The transfer of MR1.3 with neutralizing
anti–IFN-g antibodies does not inhibit its ability toof animals with cGVHD. Our studies indicate that IFN-g
mediates dose-dependent inhibition of both nephrito- adoptively transfer renal inflammation and damage,
whereas MR1.6 nephritogenicity in IFN-g–treated micegenic MR1.3 and non-nephritogenic MR1.6 prolifera-
tion, although cytokine gene expression of IL-4, IL-10, was blocked by these antibodies. In addition, both clones
constitutively express the IFN-gRb chain, which is differ-and IFN-g after IFN-g treatment is not markedly altered
in either T-cell clone following anti-CD3 Ab stimulation. entially expressed in MR1.3 and MR1.6 following IFN-g
exposure. These studies describe a remarkably permissiveWe also noted a higher baseline level of IL-13 expression
in MR1.6 compared with nephritogenic clone MR1.3. Of role for IFN-g in modulating nephritogenic Th2 activity,
perhaps by local up-regulation of renal class II MHC ornote, IFN-g markedly alters the nephritogenic potential
of clone MR1.6, as pretreated naive recipients develop costimulatory molecule expression, which facilitates the
initiation of cell-mediated autoimmune renal injury.marked renal inflammation and damage after transfer
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Table 2. Effects of IFN-g on adoptively transferred renal lesions Our studies are noteworthy in that anti–IFN-g anti-
body does not block nephritogenicity of MR1.3, indicat-Cells Recipient Severity of Depth of
transferreda treatment renal damage lesion ing that initiating renal disease by this T-cell clone is
MR1.3 PBS 1.560.5b 2267.5b not critically dependent on IFN-g. Other inflammatory
MR1.3 IFN-g 1.460.3b 2864.8b mediators produced by MR1.3, such as perforin (unpub-
MR1.6 PBS 0 0
lished observation), may be more relevant to initiatingMR1.6 IFN-g 1.760.2b 2563.0b
MR1.6 PBS 0 0 this renal immune response. Anti–IFN-g antibody was
MR1.6 IFN-g 0 0 effective, however, at blocking MR1.6 disease activity in
MR1.3 Anti-IFN-g Ab 1.5 60.1b 2864.3b
IFN-g–pretreated mice, suggesting a primary initiatingMR1.3 Rat IgG 1.260.3b 2062.9b
role for IFN-g in MR1.6 adoptively transferred lesions.a Five days following transfer of 10 3 106 MR clones to normal B6D2 F1 mice,
kidneys were harvested and evaluated by light microscopy, as detailed in the Such observations further demonstrate functional differ-
Methods section. Some recipients were injected with IFN-g (1000 U) or PBS ences between these clones, as they exhibit distinct re-IP 24 hours prior to subcapsular transfer. For some studies, MR cells were
coadministered to recipient mice with anti-IFN-g antibody or an irrelevant anti- sponses to IFN-g exposure in the setting of renal injury.
body (Rat IgG) (N 5 4–6/group). Recent studies on IFN-gR have shed light on IFN-b P , 0.001 vs. no cell/PBS control
g–mediated effects on distinct T-cell subsets [24, 31].
T-cell responsiveness to IFN-g depends on IFN-gRb
chain expression, the receptor subunit required for sig-
naling, which is limited to Th2 cells and is virtually absentThe previous observation of differential IFN-g expres-
sion in the Th2-like MR clones was intriguing in view in Th1 cells [24, 31]. It is noteworthy that chronic Th2
cell exposure to high levels of IFN-g, greater than levelsof the proscriptive influence of IL-10 on its synthesis in
CD41 T-cell clones [12]. Although culture conditions detected in our current studies, down-regulates IFN-gRb
chain expression, and decreases Th2-responsiveness tomay effect uncharacteristic changes in cytokine gene ex-
pression in cloned T-cell lines, similar Th2-like observa- exogenous IFN-g effects [24, 31]. Interestingly, ligand-
induced receptor b-chain down-regulation does not oc-tions in other models of autoimmunity suggest that this
particular CD41 T-cell phenotype may be relevant to cur in other cell preparations, such as fibroblast cell lines
[31]. IFN-g appears to regulate expression of its owndisease expression [32–34]. Such observations include
autoreactive T-cell clones isolated from MRL/lpr mouse receptor b chain on certain cell types and thereby deter-
mines the responsiveness of these cells to subsequentkidneys and gold salt-injected Brown Norway rat lymph
nodes, as well as allergen-specific human Th2 cells [32– IFN-g exposure [24, 39, 40]. Recent studies indicate that
treatment of T cells with phorbol esters or with anti-34]. These analyses indicate that IFN-g secretion by a
Th2-like CD41 T cell may be of functional significance CD3 antibodies induces IFN-gRb chain mRNA [40].
These findings demonstrate that b-chain expression canin vivo [32–34].
These MR clone studies indicate that IFN-g down- be regulated either positively or negatively in a stimulus-
specific manner [39]. Our observations of IFN-gRb chainregulates proliferation of IL-4–producing CD41 T cells
by limiting their ability to respond to T-cell growth- expression also indicate distinct responses and regulation
of this signaling chain in MR1.3 and MR1.6 cells, sug-promoting cytokines generated on activation via the
TCR complex, rather than by inhibiting the production gesting that different patterns of b-chain regulation in
these T cells may indeed cause disparate functional re-of relevant cytokines. It is intriguing, however, that de-
spite the proscriptive influence on MR1.3 and MR1.6 sponses in vivo.
Different baseline IL-13 expression in distinct MRproliferation in vitro, both T-cell clones affected renal
inflammation and damage in IFN-g–treated recipients. clones is worthy of further comment, in view of the
distinct functions mediated by these T cells. MR1.3 isIFN-g–induced up-regulation of class II MHC and rele-
vant costimulatory molecule (that is, B7-1) expression, nephritogenic, adoptively transferring tubulointerstitial
inflammation and damage to syngeneic recipients, and isas well as cytokine production, in both professional and
“nonprofessional” APCs may markedly alter patterns of restricted by Iad [11]. MR1.6, however, does not transfer
renal disease to naive syngeneic animals and is restrictedT-cell activation in vivo. In addition to these proinflam-
matory effects, IFN-g also modulates T-cell biology by Iab determinants [11]. Both MR1.3 and MR1.6 express
a predominantly Th2 cytokine pattern with IL-4, IL-6,through a number of antagonistic interactions with other
T-cell–derived cytokines [10]. For instance, although IL-10, and IL-13 expression, although our current studies
suggest that MR1.6 expresses a higher level of IL-13 onIFN-g counteracts IL-4–induced proliferation, IL-4, in-
hibits transcriptional activation of IFN-g–inducible pro- stimulation. Sharing many properties with IL-4, IL-13
also has pleiotrophic effects on B cells, monocytes, mac-teins, and blocks IFN-g–induced chemokine synthesis,
it also inhibits Th1 IFN-g production [35–37]. Similarly, rophages, and neutrophils [41]. It largely suppresses
T-cell–mediated immune responses [41]. The relativelyIFN-g suppresses Th2 cell IL-10 production, whereas IL-
10 inhibits Th1 cell IFN-g production [28, 38]. low level of IL-13 expression in nephritogenic clone
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Fig. 4. Renal class II major histocompatibility complex (MHC) expression in adoptive transfers. Kidneys harvested from adoptive transfer
experiments, three days after T cell transfers, were evaluated immunohistochemically for class II MHC (I-Ab) expression. Marked expression is
seen in (A) (MR1.3 transfer after PBS pretreatment), (B) (MR1.3 transfer after IFN-g pretreatment), and (D) (MR1.6 transfer after IFN-g
pretreatment), whereas class II MHC expression is not observed in (C) (MR1.6 transfer after PBS pretreatment) and (F) (PBS treatment control).
A minimal increase in class II MHC staining is apparent in (E) (IFN-g treatment control).
Table 3. Effects of neutralizing anti-IFN-g antobodies on IFN-g–induced changes in host environment causes a
MR1.6-induced renal lesions
dramatic change in the functional phenotype of MR1.6
Cells Recipient Severity of Depth of on adoptive transfer. Although IL-13 has been detected
transferreda treatment renal damage lesion in diseased kidneys in other models of immune-mediated
MR1.6 IFN-g, Anti-IFN-g Ab 0 0 renal disease, its immunomodulatory role in renal in-
MR1.6 IFN-g, Rat IgG 1.3 60.2b 2763.1b
flammation, however, has not been clearly defined [23].— PBS 0 0
A heterogeneity of IFN-g–mediated effects has beena Five days following transfer of 10 3 106 MR clones to normal B6D2 F1 mice,
kidneys were harvested and evaluated by light microscopy, as detailed in the reported in a number of models of autoimmune disease.
Methods section. Some recipients were injected with IFN-g (1000 U) or PBS Previous studies conducted in this model of cGVHDIP 24 hours prior to subcapsular transfer. For some studies, MR cells were
coadministered to recipient mice with anti-IFN-g antibody or an irrelevant anti- examined the effects of exogenous IFN-g on induction of
body (Rat IgG) (N 5 4–6/group). disease in B6D2 F1 mice [42]. Although IFN-g reducedb P , 0.001 vs. no cell/PBS control
serum IgE and IgG1 levels in affected mice, no difference
in animal survival was noted [42]. The extent of renal
involvement and degree of proteinuria, however, were
not evaluated [42]. In murine models such as autoim-MR1.3 may facilitate the cell-mediated inflammatory re-
mune diabetes, autoimmune thyroiditis, and lupus-pronenal lesion apparent on adoptive transfer, a response not
(NZB/NZW) F1 mice, IFN-g facilitated disease induc-significantly altered by IFN-g. Despite the apparent ro-
tion, whereas administration of anti–IFN-g antibodiesbust IL-13 expression in MR1.6, however, it is notewor-
were disease protective [43–47]. Observations in experi-thy that IFN-g pretreatment effectively alters its nephri-
togenic potential in vivo. This response suggests that mental autoimmune encephalomyelitis (EAE) and adju-
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have also identified a correlation between class II MHC
antigen induction and the pattern of lymphocytic paren-
chymal lesions observed in affected animals [52–54]. In-
creased renal class II MHC expression is likely not suffi-
cient for inducing autoimmune injury, however, as class
II MHC transgenic animals, with high levels of renal
tubular epithelial cell class II MHC expression, do not
develop spontaneous renal disease [55]. Recent in vitro
observations also indicate that IFN-g alters epithelial
cell permeability [56]. This cytokine-mediated change in
epithelial permeability may be a major cause of altered
epithelial barrier function in vivo. Such a change could
be pathogenic, as it would facilitate access of relevant
Fig. 5. Interferon (IFN)-gRb chain expression in mouse renal (MR) lymphocytic/inflammatory cells to epithelial surfaces,
clones following IFN-g exposure. Clonal RNA was harvested from promoting inflammation [56]. The potential relevance ofnonnephritogenic clone MR1.6 (A, B) and nephritogenic clone MR1.3
these IFN-g-tubular epithelial interactions is currently(C, D) and was evaluated for IFN-gRb chain expression by Northern
hybridization. MR cells were either unstimulated (A, C) or plated on under investigation in our laboratory.
immobilized anti-CD3 antibody (1 mg/ml) in the presence of IFN-g
(100 U/ml) for 24 hours (B, D). The findings are representative of three
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disease induction exacerbates disease activity. If given
Abbreviations used in this article are: cGVHD, chronic graft vs.
one to two days after disease induction, however, the host disease; EAE, experimental autoimmune encephalomyelitis; FCS,
fetal calf serum; IFN-g, interferon g; IFN-gRb, interferon g receptordisease is suppressed [51]. These disparate observations
b; IL, interleukin; MHC, major histocompatibility complex; MR, renalregarding activity of IFN-g in autoimmune tissue de-
cells isolated from mice with chronic graft vs. host disease; MR1.3,
struction further illustrate the complex, likely multistage nephritogenic T cell clone; MR1.6, non-nephritogenic T cell clone;
PBS, phosphate buffered saline; Th2, T helper cell type 2.nature of T-cell–mediated autoimmune responses. Bidi-
rectional effects noted in various disease models may be
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